Cellbxhealth (CLBX) Competitors

GBX 0.61 +0.01 (+1.00%)
As of 03:39 AM Eastern

CLBX vs. OKYO, IMM, AOR, OBD, and NSCI

Should you buy Cellbxhealth stock or one of its competitors? Cellbxhealth's main competitors and comparable companies include OKYO Pharma (OKYO), ImmuPharma (IMM), AorTech International (AOR), Oxford BioDynamics (OBD), and NetScientific (NSCI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cellbxhealth compare to OKYO Pharma?

Cellbxhealth (LON:CLBX) and OKYO Pharma (LON:OKYO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Cellbxhealth has higher revenue and earnings than OKYO Pharma. Cellbxhealth is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M5.98N/A-£3.49N/A
OKYO PharmaN/AN/A-£6.70M-£0.01N/A

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
OKYO Pharma Neutral

0.6% of Cellbxhealth shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by company insiders. Comparatively, 31.9% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cellbxhealth's return on equity of 0.00% beat OKYO Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
OKYO Pharma N/A -397.13%-154.72%

Summary

Cellbxhealth beats OKYO Pharma on 5 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to ImmuPharma?

Cellbxhealth (LON:CLBX) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
ImmuPharma Neutral

ImmuPharma has a net margin of 3,519.56% compared to Cellbxhealth's net margin of 0.00%. Cellbxhealth's return on equity of 0.00% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
ImmuPharma 3,519.56%-559.87%-43.00%

Cellbxhealth has higher revenue and earnings than ImmuPharma. ImmuPharma is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M5.98N/A-£3.49N/A
ImmuPharmaN/AN/A-£2.51M-£0.83N/A

0.6% of Cellbxhealth shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by insiders. Comparatively, 6.2% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cellbxhealth and ImmuPharma tied by winning 4 of the 8 factors compared between the two stocks.

How does Cellbxhealth compare to AorTech International?

AorTech International (LON:AOR) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Cellbxhealth is trading at a lower price-to-earnings ratio than AorTech International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AorTech International£539K0.00N/A-£3.70N/A
Cellbxhealth£1.15M5.98N/A-£3.49N/A

In the previous week, AorTech International's average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
AorTech International Neutral
Cellbxhealth Neutral

Company Net Margins Return on Equity Return on Assets
AorTech InternationalN/A N/A N/A
Cellbxhealth N/A N/A N/A

0.6% of Cellbxhealth shares are held by institutional investors. 1.2% of Cellbxhealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cellbxhealth beats AorTech International on 5 of the 5 factors compared between the two stocks.

How does Cellbxhealth compare to Oxford BioDynamics?

Oxford BioDynamics (LON:OBD) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

Cellbxhealth has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -825.61%. Cellbxhealth's return on equity of 0.00% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Cellbxhealth N/A N/A N/A

In the previous week, Oxford BioDynamics' average media sentiment score of 0.76 beat Cellbxhealth's score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the media.

Company Overall Sentiment
Oxford BioDynamics Positive
Cellbxhealth Neutral

Cellbxhealth has lower revenue, but higher earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M11.36-£103.52M-£0.20N/A
Cellbxhealth£1.15M5.98N/A-£3.49N/A

11.7% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 0.6% of Cellbxhealth shares are held by institutional investors. 53.2% of Oxford BioDynamics shares are held by company insiders. Comparatively, 1.2% of Cellbxhealth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Oxford BioDynamics beats Cellbxhealth on 6 of the 10 factors compared between the two stocks.

How does Cellbxhealth compare to NetScientific?

NetScientific (LON:NSCI) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Cellbxhealth has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. Cellbxhealth's return on equity of 0.00% beat NetScientific's return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Cellbxhealth N/A N/A N/A

Cellbxhealth has lower revenue, but higher earnings than NetScientific. Cellbxhealth is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
Cellbxhealth£1.15M5.98N/A-£3.49N/A

14.7% of NetScientific shares are owned by institutional investors. Comparatively, 0.6% of Cellbxhealth shares are owned by institutional investors. 42.4% of NetScientific shares are owned by company insiders. Comparatively, 1.2% of Cellbxhealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, NetScientific's average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
NetScientific Neutral
Cellbxhealth Neutral

Summary

NetScientific and Cellbxhealth tied by winning 4 of the 8 factors compared between the two stocks.

Get Cellbxhealth News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLBX vs. The Competition

MetricCellbxhealthBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£6.89M£4.02B£7.72B£2.74B
Dividend YieldN/A3.63%2.47%5.11%
P/E Ratio-0.1726.5432.9523.17
Price / Sales5.9815.698.215.06
Price / CashN/A22.7220.8520.23
Price / BookN/A4.164.432.46
Net IncomeN/A-£23.99M£3.51B£5.88B
7 Day Performance-1.46%-5.89%-4.73%-1.74%
1 Month Performance-26.99%-7.78%-5.69%-3.52%
1 Year PerformanceN/A-5.69%-1.18%6.90%

Cellbxhealth Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLBX
Cellbxhealth
N/AGBX 0.61
+1.0%
N/AN/A£6.89M£1.15MN/A114
OKYO
OKYO Pharma
N/AN/AN/AN/A£23.24MN/AN/A7
IMM
ImmuPharma
N/AGBX 3.24
-2.0%
N/A-72.3%£20.23MN/AN/A13
AOR
AorTech International
N/AN/AN/AN/A£19.99M£539KN/A3
OBD
Oxford BioDynamics
N/AGBX 0.11
flat
N/A-63.3%£14.79M£1.20MN/A45

Related Companies and Tools


This page (LON:CLBX) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners